![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
A Predictive Tool for Selecting HBeAg-Positive Chronic Hepatitis B Patients Who Have a High Probability of HBV DNA Suppression and HBeAg Seroconversion with Peginterferon Alfa-2a
|
|
|
Reported by Jules Levin
AASLD 2014 Nov 7-11 Boston
H.L.-Y. Chan1, G.V. Papatheodoridis2, D. Messinger3, G. Bakalos4, P. Lampertico5
1Department of Medicine and Therapeutics, Institute of Digestive Disease and State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China; 2Department of Gastroenterology, Athens University Medical School, Laiko General Hospital, Athens, Greece; 3IST GmbH, Mannheim, Germany; 4F. Hoffmann-La Roche Ltd, Basel, Switzerland; 5AM & A Migliavacca Center for Liver Disease, 1st Gastroenterology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy
![AASLD1.gif](../images/010915/010915-3/AASLD1.gif)
![AASLD2.gif](../images/010915/010915-3/AASLD2.gif)
![AASLD3.gif](../images/010915/010915-3/AASLD3.gif)
![AASLD4.gif](../images/010915/010915-3/AASLD4.gif)
![AASLD5.gif](../images/010915/010915-3/AASLD5.gif)
![AASLD6.gif](../images/010915/010915-3/AASLD6.gif)
![AASLD7.gif](../images/010915/010915-3/AASLD7.gif)
![AASLD8.gif](../images/010915/010915-3/AASLD8.gif)
![AASLD9.gif](../images/010915/010915-3/AASLD9.gif)
![AASLD10.gif](../images/010915/010915-3/AASLD10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|